Using Depo-Provera (depot medroxyprogesterone acetate, or DMPA) beyond two years triggers concerns primarily because of bone density loss, which prompted the FDA to add its strongest warning label to the drug in 2004. But bone is only part of the story. Longer use has also been linked to shifts in body fat, unfavorable cholesterol changes, a delayed return to fertility, and more recently, a small but real increase in the risk of a type of brain tumor called meningioma. How much any of these matters depends on your age, your health profile, and what you’re using the shot for.
Why the Two-Year Cutoff Exists
The FDA approved Depo-Provera as a contraceptive in 1992, but required the manufacturer to run a follow-up study on bone health. Twelve years later, in 2004, the agency added a black box warning stating that prolonged use causes significant bone mineral density loss and that the shot should not be used as a long-term method (generally defined as longer than two years) unless other options are inadequate.1PubMed. The FDA, contraceptive marketing approval and products liability litigation: Depo-Provera and the risk of osteoporosis A black box warning is the most serious type of safety alert short of pulling a drug from the market, and it makes many providers and patients understandably cautious.
The concern is straightforward: DMPA suppresses estrogen production, and estrogen is critical for maintaining bone. The drug essentially creates a mild, reversible version of the hormonal state seen after menopause, at least as far as the skeleton is concerned.2The Journal of Clinical Endocrinology & Metabolism. Effects of Depot Medroxyprogesterone Acetate on Bone Density and Bone Metabolism before and after Peak Bone Mass: A Case-Control Study The longer you stay on it, the more bone mineral density you lose, which in theory raises the risk of fractures later in life.
How Much Bone Do You Actually Lose?
The bone loss is real but not dramatic in absolute terms. In adolescents tracked over 24 months, spine bone density dropped about 1.5% and hip density dropped about 5.2%, while peers not on the shot were gaining bone during the same period.3PubMed Central. Bone Mineral Density in Adolescent Females Using Injectable or Oral Contraceptives: A 24 Month Prospective Study In adults, the pattern is similar: a steady decline that continues as long as you keep getting the injection, with the steepest losses in the first year or two. Importantly, in that adolescent study none of the participants fell into the range classified as osteopenia, let alone osteoporosis.
The clinical question everyone wants answered is whether this bone loss translates into broken bones. The honest answer is that the evidence is thin. Reviews have noted that while reduced bone density in current users has raised concerns about long-term fracture risk, large-scale fracture studies specifically in DMPA users are lacking.4Springer Link / PubMed Central. Update on hormonal contraception and bone density Bone density is a proxy for fracture risk, not a perfect predictor. Many women with modestly reduced density never fracture, and some women with normal density do. The two-year warning is precautionary, based on the density measurements rather than a proven spike in fractures.
Does Bone Come Back After You Stop?
This is the most reassuring part of the research. Multiple studies tracking women after they stopped Depo-Provera found that bone density rebounds substantially, and in many cases fully. A review of the available data found that density consistently moved back toward baseline in women of all ages, with recovery visible as early as six months after the last injection. Former users eventually had bone density similar to women who had never used the shot at all.5PubMed. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use
That said, recovery is not instantaneous, and longer use means a longer climb back. One study following first-time users over four years found that after stopping, bone density increased by about 0.3% to 2.0% per year depending on the bone site and how long the woman had been on DMPA. Women who used it the longest were still about 3–5% below their starting hip and spine values a year and a half after stopping.6PubMed. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate Another study that followed women for two full years after discontinuation found an average gain of about 6.4% in the lumbar spine, suggesting that even after prolonged use the bone loss may be almost completely reversible.7PubMed. Recovery of bone density in women who stop using medroxyprogesterone acetate
For most healthy women in their twenties and thirties, this recovery pattern is encouraging. The two-year guideline is still worth respecting when alternatives exist, but the data do not support the idea that extended use causes permanent skeletal damage in the typical user.
Adolescents and Young Women Face a Different Calculus
Teens and women in their early twenties are still building peak bone mass, which is the maximum bone density your skeleton will ever reach. Anything that interferes with that process during the critical window has the potential to leave you with a lower lifetime peak, and a lower peak means less of a buffer against the natural bone loss that comes with aging and menopause.
A study of adolescent DMPA users found continuous bone density losses at the hip and spine that extended beyond 24 months. The reassuring finding was that after stopping, significant gains were observed, suggesting the loss is apparently reversible even in this age group.8JAMA Pediatrics. Change in Bone Mineral Density Among Adolescent Women Using and Discontinuing Depot Medroxyprogesterone Acetate Contraception Still, some experts urge caution about prescribing DMPA to very young adolescents who have not yet reached peak bone mass, especially for use beyond five years.9PubMed. Effects of hormonal contraceptives on bone mineral density The concern is not that a teenager’s bones will shatter on the shot; rather, it is that the long-term trajectory could be less favorable if years of bone-building time are spent in a low-estrogen state.
The Meningioma Connection
In 2024 and 2025, research emerged linking DMPA to a type of brain tumor called a meningioma. Meningiomas grow from the membranes surrounding the brain. They are almost always benign in the strict cancer sense, but they can cause serious neurological problems depending on size and location, and treatment often involves surgery.
A large U.S. study found that DMPA use was associated with roughly two-and-a-half times the risk of being diagnosed with a meningioma compared with non-users. The risk was concentrated among women who used the shot for more than four years or who started it after age 31.10PubMed Central. Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US A separate case-control analysis found a dose-response pattern: women with more than three years of DMPA exposure had roughly two-and-a-half times the odds of meningioma compared with non-users, while those with a year or less of exposure had a more modest increase.11EClinicalMedicine. What Happens If You Take Depo-Provera for More Than 2 Years?
Before this triggers panic, some context helps. Meningiomas are rare in reproductive-age women. Doubling or tripling a very small baseline risk still leaves the absolute risk small. But the finding is relevant for women considering long-duration use, particularly those already over 30 or those with other risk factors for meningiomas (such as a history of cranial radiation). The research is too new for guidelines to have formally changed, but it adds another reason to periodically reassess whether continuing the shot is the best choice.
Weight Gain and Body Composition
Weight gain is one of the most commonly reported side effects and one of the top reasons women stop the shot. The research confirms that it happens, though the magnitude varies a lot between individuals. One study found that DMPA users gained an average of about 6 kilograms (roughly 13 pounds) over 30 months, while a control group using no hormonal method stayed essentially the same weight. The gain was not just water or overall mass; fat mass increased by a similar amount, and the distribution of fat shifted toward the midsection.12International Journal of Obesity. Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception
Other data paint a more moderate picture. A study that adjusted for age, starting weight, and number of injections found an overall average gain of about 2.4 kilograms. Adolescents gained more than adults, and women who started out underweight gained the most, while women who were already in the obese range actually tended to lose a small amount of weight.13PubMed Central. Depo-medroxyprogesterone acetate, weight gain and amenorrhea among obese women adolescent and adult women The practical takeaway is that weight gain is a real but highly variable side effect. If you notice significant gain in the first six to twelve months, it is unlikely to reverse on its own while you stay on the shot, and it may be worth discussing alternatives with your provider.
Cholesterol and Cardiovascular Markers
Long-term DMPA use shifts blood lipid profiles in an unfavorable direction. Studies comparing long-term users to non-users have consistently found higher total cholesterol, higher LDL (the “bad” cholesterol), higher triglycerides, and lower HDL (the “good” cholesterol) among those on the shot.14PubMed Central. Effects of long-term use of depo-medroxyprogesterone acetate on lipid metabolism in Nepalese women 15PubMed. Cardiovascular Disease Risk Associated With the Long-term Use of Depot Medroxyprogesterone Acetate One older study noted that cholesterol levels were significantly elevated by two to three years of use, with triglycerides initially dropping but then returning to normal by five years.16Contraception. Long-term effects of Depo-Provera on carbohydrate and lipid metabolism
None of these studies have directly shown that DMPA users suffer more heart attacks or strokes, so the clinical meaning of these lipid shifts remains uncertain. But combined with the weight gain and central fat redistribution discussed above, there is a plausible metabolic picture that deserves monitoring if you are using the shot for years on end, especially if you have other cardiovascular risk factors like smoking, family history, or existing high cholesterol.
Breast Cancer Risk
The relationship between DMPA and breast cancer has been studied for decades, and the picture is nuanced. A case-control study found that recent DMPA use for a year or longer was associated with roughly a twofold increased risk of invasive breast cancer in women aged 20 to 44. The elevated risk appeared to go away after stopping.17PubMed Central. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age A systematic review found that in general, longer duration of DMPA use did not consistently raise breast cancer risk, though one included study flagged that women who used the shot for six years or more, and especially those who started before age 25 or before their first full-term pregnancy, might face a higher risk.18PubMed Central. Depot medroxyprogesterone acetate and breast cancer: a systematic review
A more recent large study added some counterweight: former DMPA users and those with short-to-medium recent use did not show a statistically significant elevation in breast cancer risk. There was a suggestive but not definitive increase among recent long-term users.19JNCI: Journal of the National Cancer Institute. Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers Taken together, the evidence does not point to a large or lasting cancer signal from DMPA, but the possibility of a modest increase during active use, especially long use, has not been ruled out. Breast cancer is rare in women under 45, so even a doubled relative risk translates to a small number of additional cases. Still, it is worth weighing if you have a strong family history or other breast cancer risk factors.
Getting Pregnant After Stopping
Depo-Provera has a well-known reputation for delaying the return to fertility, and this is one concern that is completely legitimate. Most women will not ovulate for several months after their last injection, and for some it can take nine months to a year or longer before normal cycles resume. A study in Thailand found no evidence that prolonged DMPA use increased the delay compared with shorter use: the wait was similar whether a woman had been on the shot for two years or five. Fertility did come back in virtually all former users, and women who had never been pregnant before returned to fertility at about the same rate as those who had.20PubMed. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand
The delay is not a sign of permanent damage; it reflects how long the drug takes to clear your system and how long it takes the ovaries to resume normal hormone production. If you plan to become pregnant within the next year, switching to a shorter-acting method ahead of time makes practical sense.
Mood and Depression
Many women worry that the shot worsens depression, and this fear is often cited as a reason to stop. The available data are more reassuring than the anecdotes suggest. A study that evaluated nearly 500 women before starting DMPA and again a year later found that among continuing users, depressive symptom scores actually improved slightly. Women with the worst scores at enrollment showed the most improvement. Women who discontinued tended to have had higher baseline depression scores to begin with.21PubMed. Depressive symptoms and Depo-Provera This does not mean that no individual ever experiences mood changes on the shot; hormonal responses are highly personal. But the population-level evidence does not support the idea that DMPA systematically worsens depression.
When Longer Use Might Make Sense Anyway
Despite the warnings, there are clinical situations where providers and patients reasonably decide that extended DMPA use is the best option. Endometriosis is one of the most common examples. The shot has been shown to reduce endometriosis-related pain as effectively as leuprolide (a drug specifically designed to treat endometriosis), with less bone density loss and fewer menopausal-type side effects.22PubMed. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain 23PubMed. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis For women managing severe menstrual bleeding, heavy periods related to fibroids, or conditions where estrogen-containing methods are contraindicated, the shot can be genuinely life-improving. In those situations, the two-year guideline becomes a factor to weigh rather than an absolute cutoff.
How Other Long-Acting Methods Compare on Bone
If bone health is your primary worry, the good news is that other long-acting progestin methods do not appear to carry the same risk. A recent rapid review found a clear link between any DMPA use and bone mineral density loss, but hormonal IUDs and implants did not show the same effect.24AJOG Global Reports. Bone mineral density changes during use of progestin-only contraceptives: a rapid review of recent evidence The reason likely comes down to systemic versus local hormone exposure. DMPA floods the bloodstream with progestin at levels high enough to suppress ovarian estrogen production. The hormonal IUD releases progestin mostly into the uterus, so estrogen levels stay closer to normal. The implant releases a different progestin at lower systemic doses.
Switching from Depo-Provera to a hormonal IUD or an implant gives you similarly effective long-acting contraception without the ongoing bone density trade-off. If you have been on the shot for more than two years and your provider is encouraging a switch, bone protection is the main reason, though avoiding the weight and lipid changes discussed above is an added bonus for many women. Of course, breast cancer data are not entirely clear-cut for other progestin methods either: the same large study that showed little breast cancer signal for DMPA found that hormonal IUD and implant users had a modest increase in breast cancer risk.19JNCI: Journal of the National Cancer Institute. Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers No hormonal method is completely without trade-offs.
Monitoring If You Stay on the Shot
If you and your provider decide that continuing DMPA past two years is the right call, periodic bone density screening with a DXA scan is sometimes recommended, though guidelines are not uniform. Research in adolescents and young women found that those who received more than five injections were more likely to have low spinal bone density scores on their first scan, and density continued to decline with additional injections. This kind of monitoring can help identify the women who are losing bone faster than average and might benefit most from switching methods.
Beyond bone scans, keeping tabs on weight, waist circumference, and fasting lipid panels is sensible for any long-term user, given the metabolic shifts described above. None of these risks are dramatic enough that you need to stop the shot in a panic if you realize you have been using it for three or four years, but they are collectively strong enough to justify a regular conversation with your provider about whether the benefits still outweigh the costs for your particular situation.